A new specialist clinic at The Alfred for women’s heart health, a world-first DNA screening program for cancer and heart disease, and an innovative drug that could revolutionise treatment of type 2 diabetes – this week at the Alfred Research Alliance.
Getting serious about women’s heart health
Women experiencing chest pain or other symptoms of cardiac distress now have access to a specialist clinic just for them.
Monash University – Central Clinical School
Innovative drug could improve type 2 diabetes treatment
A new drug that ‘reboots’ how fat cells use insulin could revolutionise type 2 diabetes treatment and improve the outlook of hundreds of millions of patients globally.
Monash University – School of Public Health and Preventive Medicine
A new proactive approach to staying sharp as you get older
Fewer years of formal education, diabetes, and physical inactivity have well-documented associations with dementia and cognitive decline in older age. On the flip side, we know relatively little about the factors that can help older individuals stay sharp and maintain good cognitive ability even with advancing age.
Does mindfulness practice lead to better academic performance?
The benefits of mindfulness are frequently hailed to help students manage competing work and life commitments in a healthy, balanced way that supports best learning. Medical students are no different, and many are encouraged to incorporate mindfulness into their busy lives.
World-first preventative DNA screening for cancer and heart disease risk
Young Australians can now access a free DNA saliva test to learn whether they face increased risk of some cancers and heart disease, which can be prevented or treated early if detected, in a world-first DNA screening study.
Baker Heart and Diabetes Institute
Why have so few Australians heard of MAFLD?
It has been described as a stealth killer that impacts at least one in four Australians and is rising rapidly. Disease prevalence is expected to increase by 25–50 per cent over the next 10 years, including 15–20 per cent in children. It is a risk factor for cardiovascular disease, type 2 diabetes and a common type of liver cancer, and it is expected to become the leading cause of liver transplant within the next 20 years. So why have so few Australians heard of metabolic associated fatty liver disease (MAFLD), the most common cause of liver disease?
Fast Five with Adam Parslow
Dr Adam Parslow is the keeper of our state-of-the-art microscopy equipment, including the unique multiphoton microscopy platform that has the power to cut a human hair lengthways 600 times. Adam works collaboratively with scientists and researchers across 18 of our labs and is often the first person to see discoveries in all their minute glory.
Burnet congratulates Jim and Margaret Beever Fellow and travel award recipients
Malaria researcher Dr Fiona Angrisano awarded Jim and Margaret Beever Fellowship for 2022.
Preparing for the next pandemic
The new Australian Institute for Infectious Disease (AIID) will be a key asset in responding to future pandemics and other global health challenges.